Guggenheim Starts Assembly Biosciences (ASMB) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Nasdaq climbs over 1% as AI-linked stocks recover ahead of key earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month highs with Hormuz crossings, Russian sanctions waiver in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
Tweet
Share
E-mailGet Alerts ASMB Hot Sheet
Price: $20.17 +0.40%
Rating Summary:
8 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 20 | New: 12
Rating Summary:
8 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 20 | New: 12
Join SI Premium – FREE
Guggenheim analyst Vamil Divan initiates coverage on Assembly Biosciences (NASDAQ: ASMB) with a Buy rating and a price target of $31.00.
For an analyst ratings summary and ratings history on Assembly Biosciences click here. For more ratings news on Assembly Biosciences click here.
Shares of Assembly Biosciences closed at $11.12 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DXC Technology in advanced talks to sell insurance software unit for $2.4 Billion - Reuters
- J.P. Morgan projects 7.0% return for 60/40 portfolio over 10-15 years
- Newline by Fifth Third enables fintech Visa corporate cards in 40+ countries
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Guggenheim, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
